CCChristopher Clarke

Christopher Clarke

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Christopher Clarke has a total of 188 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Simplifying CT / MRI LI ‐ RADS v2018 Maintains Diagnostic Performance: An Individual Participant Data Meta‐Analysis

    by E. Lam, M. M. G. Leeflang, R. G. Adamo, C. B. van der Pol, M. Alabousi, J. P. Salameh, H. Naringrekar, M. R. Bashir, A. F. Costa, H. Osman, et al.

    Background: The Liver Imaging Reporting and Data System (LI‐RADS) diagnostic algorithm assesses hepatocellular carcinoma (HCC) probability of liver observations in high‐risk individuals, but complexity may limit its adoption. Purpose: To evaluate whether LI‐RADS v2018 can be simplified without impairing diagnostic performance by removing threshold growth (TG) and reducing size cut‐offs. Study Type: Retrospective meta‐analysis. Population: Eight thousand five hundred eighty‐two patients (mean age: 59 ± 11 years; 6610 male) at risk for HCC with CT/MRI (986 CT, 6554 MRI, and 1042 CT/MRI). Field Strength/Sequence: Field strength: 1.5T and 3.0T; sequences varied by institution per LI‐RADS technical requirements. Assessment: LI‐RADS v2018 using major features only was compared with seven simplifications removing TG and/or applying single size cut‐offs (≥ 10, ≥ 15, and ≥ 20 mm) in individual participant data (IPD) of 64 studies (29 institutions, 11 countries) from the LI‐RADS Living Systematic Review and IPD Meta‐analysis Project. Risk of bias was assessed with QUADAS‐2. Statistical Tests: Summary receiver operating characteristic curves estimated area under the curve (AUC) across LR‐3 to LR‐5; LR‐5 sensitivity, specificity, and positive predictive value (PPV) were estimated using a one‐step bivariate mixed‐effects model. Differences were assessed by cluster bootstrap. p < 0.05 indicated significance, uncorrected for multiple comparisons. Results: Nine thousand four hundred six observations were included. Excluding TG with a 10‐mm cut‐off showed AUC similar to LI‐RADS v2018 (0.80 vs. 0.81, p = 0.44) and significantly higher LR‐5 sensitivity (73.8% vs. 71.8%) with similar specificity (72.5% vs. 73.7%, p = 0.13) and PPV (97.8% vs. 97.8%, p = 0.73). Removing TG with 15‐mm and 20‐mm cut‐offs had significantly lower AUC than v2018 (−0.03 [95% CI: −0.041, −0.019]; −0.043 [−0.054, −0.032], respectively) and sensitivity (−13.2% [95% CI: −14.5%, −12.0%]; −30.1% [−31.7%, −28.5%], respectively). Of the 64 studies, 17 had low‐risk of bias, and 56 had low applicability concerns. Conclusion: Simplifying LI‐RADS v2018 by removing TG and using a 10‐mm size cut‐off preserved diagnostic table AUC while improving LR‐5 sensitivity without loss of specificity or PPV. Protocol Registration: Open Science Framework ( https://osf.io/cjwgp ). Evidence Level: 3. Technical Efficiency: Stage 2.


  • Open Access

    Inter‐Reader Agreement for CT and MRI LI ‐ RADS Version 2018: An Individual Participant Data Meta‐Analysis

    by S. Das, E. Lam, O. Muhn, S. Mahbub, D. Ansari, H. Osman, R. Awad, M. K. Al‐Ghita, R. Thornhill, C. Walsh, et al.

    Background: The Liver Imaging Reporting and Data System (LI‐RADS) is a classification system to diagnose hepatocellular carcinoma (HCC) noninvasively. The reported LI‐RADS inter‐reader variability in single‐center studies highlights the need to better understand the variability on a broader scale. Purpose: Evaluate inter‐reader agreement for LI‐RADS CT/MRI v2018 categorization and imaging features using individual participant data (IPD) meta‐analysis for MRI and CT separately. Study Type: Retrospective meta‐analysis. Population: 805 patients (542 male, mean age 60.8 ± 11.6 [SD] years) at risk of HCC. Field Strength/Sequence: 1.5 and 3 T, Sequences varied across institutions but followed standard LI‐RADS protocols. Assessment: Studies from the LI‐RADS Living IPD Meta‐Analysis Project were used. Inclusion criteria: observations evaluated by > 1 reader using LI‐RADS CT/MRI v2018. Risk of bias was assessed for the index test domain using QUADAS‐2; sensitivity analysis was conducted excluding high‐risk observations. The developed protocol is available on the Open Science Framework ( https://osf.io/tdv7j/files/6kh7s ). Statistical Tests: A two‐step meta‐analytic approach was used to determine pooled kappa ( κ ) with heterogeneity assessed using τ 2 and I 2 . A post hoc univariable meta regression was conducted using the following variables: number of readers, reader experience, feature prevalence, and study country. Statistical significance was defined as two‐tailed p < 0.05. Results: Five studies (three CT and MRI, two MRI) comprising 975 observations were included. Four studies had two readers, and one had three, most readers were specialized abdominal radiologists (3–33 years' experience). Inter‐reader agreement ( κ ) for major features was 0.21–0.74 on MRI and 0.11–0.75 on CT. For Ancillary features, κ was −0.02 to 0.68 for MRI and −0.02 to 0.58 on CT, and LR‐M agreement was −0.07 to 0.58 on MRI and −0.07 to 0.66 on CT. LI‐RADS categorization showed agreement of κ = 0.76 for MRI and κ = 0.50 for CT. Data Conclusion: MRI consistently reported higher agreement than CT for shared features, but overall inter‐reader agreement was variable. Evidence Level: 3. Technical Efficacy: Stage 2: diagnostic accuracy, considered by most as clinical efficacy.


  • Open Access

    The expanding cancer landscape in chronic pancreatitis

    by Shauntelle Quammie, Adil Rashid, Rahul Munyal, Edward S. Nicholson, Christopher Clarke, Suresh Vasan Venkatachalapathy, Colin John Crooks, Guruprasad P. Aithal, Aloysious D. Aravinthan


  • Diagnostic Performance of CT/MRI LI-RADS Version 2018 Major Feature Combinations: Individual Participant Data Meta-Analysis

    by Robert G. Adamo, Christian B. van der Pol, Mostafa Alabousi, Eric Lam, Jean-Paul Salameh, Nicole Abedrabbo, Emily Lerner, Haresh Naringrekar, Mustafa R. Bashir, Andreu F. Costa, et al.

    This meta-analysis showed that most major feature combinations in the same CT/MRI Liver Imaging Reporting and Data System category had similar positive predictive values for hepatocellular carcinoma in patients at high risk for cancer, with the exception of five combinations from LR-3 to LR-5.


  • Open Access

    Autologous stem cell transplantation with low-dose cyclophosphamide to improve mucosal healing in adults with refractory Crohn’s disease: the ASTIClite RCT

    by James O Lindsay, Daniel Hind, Lizzie Swaby, Hannah Berntsson, Mike Bradburn, Uday Bannur C, Jennifer Byrne, Christopher Clarke, Lauren Desoysa, Shahida Din, et al.

    Some text in this abstract has been reproduced from Lindsay J, Din S, Hawkey C, Hind D, Irving P, Lobo A, et al. OFR-9 An RCT of autologous stem-cell transplantation in treatment refractory Crohn’s disease (low-intensity therapy evaluation): ASTIClite. Gut 2021;70(Suppl. 4):A4. Background: Treatment-refractory Crohn’s disease is characterised by chronic symptoms, poor quality of life and high costs to the NHS, and through days of work lost by patients. A previous trial of autologous haematopoietic stem cell transplant (HSCT) failed its end point of medication-free clinical remission for 3 months with no evidence of disease activity, and reported high toxicity. Subsequent studies suggest that HSCT achieves complete mucosal healing in 50% of patients, and that toxicity likely relates to the cyclophosphamide dose. Objectives: The primary objective was to assess the efficacy of HSCTlite (HSCT with low-dose cyclophosphamide) compared with standard care for inducing regression of intestinal ulceration in patients with refractory Crohn’s disease at week 48. Secondary objectives included the assessment of disease activity, quality of life and regimen safety. Mechanistic objectives included immune reconstitution after HSCTlite. Design: Two-arm, parallel-group randomised controlled trial with a 2 : 1 (intervention : control) allocation ratio. Setting: Nine NHS trusts (eight trusts were recruitment sites; one trust was a treatment-only site). Participants: Adults with treatment-refractory Crohn’s disease, for whom surgery was inappropriate or who had declined surgery. Interventions: The intervention treatment was HSCTlite using cyclophosphamide, and the control was any current available treatment for Crohn’s disease, apart from stem cell transplantation. Main outcomes: The primary outcome was treatment success at week 48 [mucosal healing (Simple Endoscopic Score for Crohn’s Disease ulcer subscore of 0) without surgery or death], assessed by central readers blinded to allocation and timing of assessment. Key secondary outcomes were clinical remission, Simple Endoscopic Score for Crohn’s Disease scores at week 48, change in Crohn’s Disease Activity Index scores and safety. Results: The trial was halted owing to Suspected unexpected serious adverse events that took place after randomising 23 patients (HSCTlite arm, n = 13; usual-care arm, n = 10). Ten out of the 13 patients randomised to the HSCTlite arm received the intervention and nine (one death) reached the 48-week follow-up. In the usual-care arm 9 out of the 10 patients randomised reached the 48-week follow-up (one ineligible). The primary outcome was available for 7 out of 10 HSCTlite patients (including the patient who died) and six out of nine usual-care patients. Absence of endoscopic ulceration without surgery or death was reported in three out of seven (43%) HSCTlite patients, compared with zero out of six (0%) usual-care patients. Centrally read Simple Endoscopic Score for Crohn’s Disease scores [mean (standard deviation)] were 10.8 (6.3) and 10.0 (6.1) at baseline, compared with 2.8 (2.9) and 18.7 (9.1) at week 48, in the HSCT and usual-care arms, respectively. Clinical remission (Crohn’s Disease Activity Index scores of < 150) occurred in 57% and 17% of patients in the HSCTlite and usual-care arms, respectively, at week 48. Serious adverse events were more frequent in the HSCTlite arm [38 in 13 (100%) patients] than in the usual-care arm [16 in 4 (40%) patients]. Nine suspected unexpected serious adverse reactions were reported in six HSCTlite patients, including three cases of delayed renal failure due to proven thrombotic microangiopathy. Two HSCTlite patients died. Conclusions: Within the limitations of reduced patient recruitment and numbers of patients assessed, HSCTlite meaningfully reduced endoscopic disease activity, with three patients experiencing resolution of ulceration. Suspected unexpected serious adverse reactions, particularly relating to thrombotic microangiopathy, make this regimen unsuitable for future clinical use. Limitations: The early trial closure prevented complete recruitment, and the impact of the coronavirus pandemic prevented completion of some study investigations. Small participant numbers meant analysis could only be descriptive. Future work: Owing to undetermined aetiology of thrombotic microangiopathy, further trials of HSCTlite in this population are not considered appropriate. Priorities should be to determine optimal treatment strategies for patients with refractory Crohn’s disease, including those with a stoma or multiple previous resections. Trial registration: This trial is registered as ISRCTN17160440 and EudraCT 2017-002545-30. Funding: This award was funded by the Efficacy and Mechanism Evaluation (EME) programme, a Medical Research Council (MRC) and National Institute for Health and Care Research (NIHR) partnership. This is published in full in Efficacy and Mechanism Evaluation; Vol. 11, No. 3. See the NIHR Funding and Awards website for further award information.


  • Individual Participant Data Meta-Analysis of LR-5 in LI-RADS Version 2018 versus Revised LI-RADS for Hepatocellular Carcinoma Diagnosis

    by Stacy M. Goins, Hanyu Jiang, Christian B. van der Pol, Jean-Paul Salameh, Eric Lam, Robert G. Adamo, Matthew D. F. McInnes, Andreu F. Costa, An Tang, Ayman S. Alhasan, et al.

    Background A simplification of the Liver Imaging Reporting and Data System (LI-RADS) version 2018 (v2018), revised LI-RADS (rLI-RADS), has been proposed for imaging-based diagnosis of hepatocellular carcinoma (HCC). Single-site data suggest that rLI-RADS category 5 (rLR-5) improves sensitivity while maintaining positive predictive value (PPV) of the LI-RADS v2018 category 5 (LR-5), which indicates definite HCC. Purpose To compare the diagnostic performance of LI-RADS v2018 and rLI-RADS in a multicenter data set of patients at risk for HCC by performing an individual patient data meta-analysis. Materials and Methods Multiple databases were searched for studies published from January 2014 to January 2022 that evaluated the diagnostic performance of any version of LI-RADS at CT or MRI for diagnosing HCC. An individual patient data meta-analysis method was applied to observations from the identified studies. Quality Assessment of Diagnostic Accuracy Studies version 2 was applied to determine study risk of bias. Observations were categorized according to major features and either LI-RADS v2018 or rLI-RADS assignments. Diagnostic accuracies of category 5 for each system were calculated using generalized linear mixed models and compared using the likelihood ratio test for sensitivity and the Wald test for PPV. Results Twenty-four studies, including 3840 patients and 4727 observations, were analyzed. The median observation size was 19 mm (IQR, 11-30 mm). rLR-5 showed higher sensitivity compared with LR-5 (70.6% [95% CI: 60.7, 78.9] vs 61.3% [95% CI: 45.9, 74.7]; P < .001), with similar PPV (90.7% vs 92.3%; P = .55). In studies with low risk of bias (n = 4; 1031 observations), rLR-5 also achieved a higher sensitivity than LR-5 (72.3% [95% CI: 63.9, 80.1] vs 66.9% [95% CI: 58.2, 74.5]; P = .02), with similar PPV (83.1% vs 88.7%; P = .47). Conclusion rLR-5 achieved a higher sensitivity for identifying HCC than LR-5 while maintaining a comparable PPV at 90% or more, matching the results presented in the original rLI-RADS study. © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Sirlin and Chernyak in this issue.


  • Open Access

    Outcomes of National Survey of the Practice of Hepatocellular Carcinoma Surveillance

    by Robert A Scott, Timothy J S Cross, Christopher Clarke, Shahid A Khan, Stephen D Ryder, James Franklin, Aloysious D Aravinthan

    Background & Aim: HCC has significantly improved outcomes when detected early. Guidelines recommend biannual surveillance with ultrasound (US) and/or AFP in at-risk individuals. This survey aimed to describe HCC surveillance adherence/practices amongst the NHS hospitals in the UK. Methods: An electronic survey was sent to 79 NHS hospitals via the British Association for the Study of the Liver distribution list. The responses were captured from July 2021 to January 2022. Centres were divided into hepato-pancreato-biliary (HPB) and non-HPB centres, depending on whether the hospital undertakes major liver surgeries. Results: A total of 39 (49.3%) centres responded: 15 HPB and 24 non-HPB centres from across the UK. HCC surveillance eligibility criteria were universally applied, but heterogeneous approaches occur outside these criteria. Eighty per cent of patients undergoing surveillance were estimated to have cirrhosis. Eighty-five per cent of centres do 6-monthly US and AFP requested by clinicians and liver clinical nurse specialists. Compliance was estimated at 80% but not routinely audited. In most centres, general sonographers and/or radiologists perform surveillance US scans without a standard reporting template, although structured reporting was viewed as desirable by the majority. Poor views on US are approached heterogeneously, with patients variably offered ongoing US, CT, or MRI with different protocols. Conclusion: Most responding NHS hospitals follow 6-monthly HCC surveillance guidance. Data recording is variable, with limited routine data collection regarding compliance, yield, and quality. Surveillance US is mostly performed by non-HPB specialists without standardised reporting. There is an inconsistent approach to poor views with US surveillance. Even in a universal healthcare system such as NHS, which is free at the point of care, delivery of HCC surveillance has not improved over the last decade and remains variable.


  • Open Access

    Quantitative Magnetic Resonance Imaging in Perianal Crohn’s Disease at 1.5 and 3.0 T: A Feasibility Study

    by Ali Alyami, Caroline L. Hoad, Christopher Tench, Uday Bannur, Christopher Clarke, Khalid Latief, Konstantinos Argyriou, Alan Lobo, Philip Lung, Rachel Baldwin-Cleland, et al.

    Perianal Crohn’s Disease (pCD) is a common manifestation of Crohn’s Disease. Absence of reliable disease measures makes disease monitoring unreliable. Qualitative MRI has been increasingly used for diagnosing and monitoring pCD and has shown potential for assessing response to treatment. Quantitative MRI sequences, such as diffusion-weighted imaging (DWI), dynamic contrast enhancement (DCE) and magnetisation transfer (MT), along with T2 relaxometry, offer opportunities to improve diagnostic capability. Quantitative MRI sequences (DWI, DCE, MT and T2) were used in a cohort of 25 pCD patients before and 12 weeks after biological therapy at two different field strengths (1.5 and 3 T). Disease activity was measured with the Perianal Crohn’s Disease Activity index (PDAI) and serum C-reactive protein (CRP). Diseased tissue areas on MRI were defined by a radiologist. A baseline model to predict outcome at 12 weeks was developed. No differences were seen in the quantitative MR measured in the diseased tissue regions from baseline to 12 weeks; however, PDAI and CRP decreased. Baseline PDAI, CRP, T2 relaxometry and surgical history were found to have a moderate ability to predict response after 12 weeks of biological treatment. Validation in larger cohorts with MRI and clinical measures are needed in order to further develop the model.